Cue Biopharma, Inc.
CUE
$0.84
$0.02182.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.29M | 7.99M | 9.29M | 9.53M | 8.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.29M | 7.99M | 9.29M | 9.53M | 8.30M |
| Cost of Revenue | 33.82M | 35.44M | 37.09M | 40.80M | 41.29M |
| Gross Profit | -25.54M | -27.45M | -27.81M | -31.27M | -32.99M |
| SG&A Expenses | 13.94M | 13.77M | 13.79M | 14.37M | 15.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.76M | 49.21M | 50.88M | 55.17M | 56.44M |
| Operating Income | -39.48M | -41.22M | -41.59M | -45.64M | -48.15M |
| Income Before Tax | -38.90M | -40.58M | -40.67M | -44.61M | -46.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.90 | -40.58 | -40.67 | -44.61 | -46.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.90M | -40.58M | -40.67M | -44.61M | -46.96M |
| EBIT | -39.48M | -41.22M | -41.59M | -45.64M | -48.15M |
| EBITDA | -39.08M | -40.82M | -41.20M | -45.23M | -47.70M |
| EPS Basic | -0.55 | -0.66 | -0.75 | -0.91 | -0.97 |
| Normalized Basic EPS | -0.35 | -0.42 | -0.47 | -0.57 | -0.61 |
| EPS Diluted | -0.55 | -0.66 | -0.75 | -0.91 | -0.97 |
| Normalized Diluted EPS | -0.35 | -0.42 | -0.47 | -0.57 | -0.61 |
| Average Basic Shares Outstanding | 295.18M | 249.90M | 225.11M | 198.07M | 193.20M |
| Average Diluted Shares Outstanding | 295.18M | 249.90M | 225.11M | 198.07M | 193.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |